奥沙利铂联合卡培他滨(XELOX)治疗晚期胃癌的疗效观察

目的观察奥沙利铂联合卡培他滨即XELOX方案治疗晚期胃癌的临床疗效和不良反应。方法38例晚期胃癌患者接受XELOX方案化疗,即:奥沙利铂L-OHP 130mg/m~2静脉滴注2h,d1;卡培他滨2000mg/m~2 d,d1-14。每3周重复。治疗2周期后按WHO实体瘤疗效评定标准评价疗效及毒副反应。38例均完成6个周期化疗。结果全组38例均可评价疗效,总有效率47.4%(18/38),中位缓解期8个月,中位生存期12个月,1年生存率为55%。其中,初治18例,CRI例,PR9例,有效率55.6%;复治20例,无CR,PR8例,有效率40.0%。不良反应主要为神经毒性,包括四肢感觉异常、冷刺激敏感、握力下降等,多数患者耐受良好,其次是恶心、呕吐、腹泻、血细胞下降等,无因毒副反应而终止治疗者,无治疗相关性死亡。结论XELOX方案治疗晚期胃癌近期疗效好,不良反应较轻,多数患者耐受,是治疗晚期胃癌的较好方案。

Clinical Analysis of Oxaliplatin Joint Capecitabine(XELOX)in the Treatment of Advanced Gastric Cancer

Objective To observe the joint oxaliplatin capecitabine that XELOX in the treatment of advanced gastric cancer clinical efficacy and side effects. Method 38 patients with advanced gastric cancer patients receiving chemotherapy XELOX, namely： oxaliplatin L - OHP 130mg / m2 intravenous infusion 2 h, d1; Capecitabine 2000 mg / m2.d, d1-14. Repeat every three weeks. After two cycles of solid tumor effect according to WHO standards evaluation assessed the efficacy and toxicity of. 38 cases were completed six cycles of chemotherapy. Results Group of 38 cases are evaluated, and the total efficiency of 47.4% （18/38）, in the eight-month remission, the median StLrvival time of 12 months, 1-year survival rate was 55 percent. Of these, 18 cases of initial treatment, CR1 cases, PR9 cases, the efficiency of 55.6 percent; re-treated 20 cases, non-CR, PR8 cases, the efficiency of 40.0 percent. Adverse reactions to the main nerve toxicity, including limbs feel very cold to stimulate sensitive, such as grip strength decline, the majority of patients with good tolerance, This was followed by nausea, vomiting, diarrhea, blood cells dropped, and so on, without reason to terminate the toxicity of treatment, no treatment-related deaths. Conclusion XELOX in the treatment of advanced gastric cancer recent good effect, less adverse reactions, most patients tolerated the treatment of advanced gastric cancer is a good programme.